Surface profiles for subclassification of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1046-1056

  Huang, Pauline Y ^a   Best, O Giles ^b   Belov, Larissa ^a   Mulligan, Stephen P ^a,b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antibodies; CD antigens; Chronic lymphocytic leukemia; Immunophenotype; Microarray; Prognosis

Indexed keywords

ALPHA4 INTEGRIN; CD2 ANTIGEN; CD20 ANTIGEN; CD200 ANTIGEN; CD38 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; DIPEPTIDYL PEPTIDASE IV; HLA G ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOCYTE ASSOCIATED IMMUNOGLOBULIN LIKE RECEPTOR 1; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; MICROARRAY ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

ANTIGENS, CD; ANTIGENS, SURFACE; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROARRAY ANALYSIS; MODELS, BIOLOGICAL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861349902     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631370     Document Type: Review

References (139)

1. Kay NE, Jelinek DF. B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood 2002;100:1110-1111.
2. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
3. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic signifi cance. Cancer 1977;40:855-864. (Pubitemid 8177910)
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classifi cation of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206. (Pubitemid 11064396)
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
6. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
7. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
8. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111. (Pubitemid 38068326)
9. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifi es a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profi le. Blood 2003;101:4944-4951. (Pubitemid 36857758)
10. Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008;140:537-546. (Pubitemid 351230080)
11. Hamblin T. Prognostic factors in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2261-2262. (Pubitemid 44768411)
12. Belov L, Huang P, Barber N, et al. Identifi cation of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003;3:2147-2154. (Pubitemid 37414081)
13. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profi le of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645. (Pubitemid 24323778)
14. Matutes E, Attygalle A, Wotherspoon A, et al. Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:3-20.
15. Belov L, Mulligan SP, Barber N, et al. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 2006;135:184-197. (Pubitemid 44401615)
16. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146-2155. (Pubitemid 37122392)
17. Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135-1144. (Pubitemid 44232007)
18. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116:142-150. (Pubitemid 34122071)
19. Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42: 109-114. (Pubitemid 32700928)
20. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16:30-35. (Pubitemid 34105596)
21. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defi nes a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-1269. (Pubitemid 36182494)
22. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-186.
23. Mainou-Fowler T, Dignum H, Taylor PR, et al. Quantifi cation improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 2002;118:755-761. (Pubitemid 35007379)
24. Boonstra JG, von' t Veer MB, Gratama JW. The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. J Biol Regul Homeost Agents 2004;18:340-346. (Pubitemid 40723675)
25. Matrai Z. CD38 as a prognostic marker in CLL. Hematology 2005;10:39-46. (Pubitemid 41093587)
26. D'Arena G, Nunziata G, Coppola G, et al. CD38 expression does not change in B-cell chronic lymphocytic leukemia. Blood 2002; 100:3052-3053.
27. Eisele L, Haddad T, Sellmann L, et al. Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. Leuk Res 2009;33:775-778.
28. Schroers R, Griesinger F, Trumper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750-758. (Pubitemid 40663094)
29. Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006;108:2950-2956.
30. Abousamra NK, El-Din MS, Azmy E. T-cell CD38 expression in B-chronic lymphocytic leukaemia. Hematol Oncol 2009;27:82-89.
31. Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012-4021. (Pubitemid 350248457)
32. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173-5181.
33. Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev 2002;186:118-124.
34. de la Fuente MT, Casanova B, Garcia-Gila M, et al. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-274. (Pubitemid 29092660)
35. de la Fuente MT, Casanova B, Moyano JV, et al. Engagement of alpha 4beta1 integrin by fi bronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fl udarabine. J Leukoc Biol 2002;71:495-502.
36. Eksioglu-Demiralp E, Alpdogan O, Aktan M, et al. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 1996;10:1331-1339. (Pubitemid 26261430)
37. Rossi D, Zucchetto A, Rossi FM, et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008;93:1575-1579.
38. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865-873.
39. Nuckel H, Switala M, Collins CH, et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 2009;131:472-480.
40. Majid A, Lin TT, Best G, et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011;35:750-756.
41. Kumpfel T, Heydari N, Hohlfeld R. Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis. Nervenarzt 2002;73:552-555. (Pubitemid 36068364)
42. Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011;155:53-64.
43. Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol 2002;68:127-134. (Pubitemid 34620600)
44. Nakase K, Kita K, Nasu K, et al. Diff erential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 1994;46:179-183. (Pubitemid 24206741)
45. Teff eri A, Bartholmai BJ, Witzig TE, et al. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997;95:173-177. (Pubitemid 27217127)
46. Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994;8:92-96. (Pubitemid 24032825)
47. Sulda ML, Kuss BJ, Hall RK, et al. The clinical utility of molecular and fl ow cytometric markers in CLL. Intern Med J 2010 Jun 15. [Epub ahead of print]
48. Capello D, Zucchetto A, Degan M, et al. Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 2006;30:1197-1199. (Pubitemid 44037077)
49. Zucchetto A, Sonego P, Degan M, et al. Signature of B-CLL with diff erent prognosis by Shrunken centroids of surface antigen expression profi ling. J Cell Physiol 2005;204:113-123. (Pubitemid 40776813)
50. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-264. (Pubitemid 34205737)
51. Buhling F, Junker U, Reinhold D, et al. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47-51.
52. Iwata S, Morimoto C. CD26/dipeptidyl peptidase IV in context. The diff erent roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 1999;190:301-306.
53. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004;19:1345-1351. (Pubitemid 39386791)
54. Cro L, Morabito F, Zucal N, et al. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol 2009;27:140-147.
55. Kamoun M, Martin PJ, Hansen JA, et al. Identifi cation of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med 1981;153:207-212. (Pubitemid 11167847)
56. Cantu-Rajnoldi A, Putti MC, Schiro R, et al. Biological and clinical features of B-precursor childhood acute lymphoblastic leukemia showing CD2 and/or E-rosette co-expression. Haematologica 1992;77:384-391. (Pubitemid 23012082)
57. Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Am J Hematol 1996;52: 224-226. (Pubitemid 26254863)
58. Uckun FM, Muraguchi A, Ledbetter JA, et al. Biphenotypic leukemic lymphocyte precursors in CD2 + CD19 + acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989;73:1000-1015. (Pubitemid 19078380)
59. Ahmad E, Steinberg SM, Goldin L, et al. Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008;74:221-226. (Pubitemid 352007319)
60. Brohee D, Cauchie P, Neve P. Co-expression of CD2 or CD8 antigens in B-cell chronic lymphocytic leukaemia. A fl ow cytometry analysis of 3 cases. Acta Clin Belg 1994;49:183-186.
61. Kingma DW, Imus P, Xie XY, et al. CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms. Cytometry 2002;50:243-248.
62. Viciana AL, Lancet FC, Chamizo W, et al. Simultaneous expression of CD2 on a B-cell, small lymphocytic neoplasm. Cytometry 1994;18:42-48. (Pubitemid 24250605)
63. Matutes E, Wechsler A, Gomez R, et al. Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br J Haematol 1981;49:635-642. (Pubitemid 12193772)
64. Kurec AS, Th reatte GA, Gottlieb AJ, et al. Immunophenotypic subclassifi cation of chronic lymphocytic leukaemia (CLL). Br J Haematol 1992;81:45-51.
65. Newman RA, Peterson B, Davey FR, et al. Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1993;82:1239-1246. (Pubitemid 23253999)
66. Kampalath B, Barcos MP, Stewart C. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2003;119:824-832. (Pubitemid 37047844)
67. Avila-Carino J, Lewin N, Tomita Y, et al. B-CLL cells with unusual properties. Int J Cancer 1997;70:1-8. (Pubitemid 27059698)
68. Carulli G, Stacchini A, Marini A, et al. Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infi ltration. Am J Clin Pathol 2009;132:186-190; quiz 306.
69. Espinosa A, Bjork P, Magnussen K, et al. Aberrant expression of the CD8 antigen in B cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:193-196. (Pubitemid 36113850)
70. Fernhout F, Dinkelaar RB, Hagemeijer A, et al. Four aged siblings with B cell chronic lymphocytic leukemia. Leukemia 1997;11:2060-2065. (Pubitemid 28043690)
71. Islam A, Vladutiu AO, Donahue T, et al. CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature. Arch Pathol Lab Med 2000;124:1361-1363.
72. Kaleem Z, White G, Zutter MM. Aberrant expression of T-cellassociated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001;115:396-403. (Pubitemid 33694837)
73. Mulligan SP, Dao LP, Francis SE, et al. B-cell chronic lymphocytic leukaemia with CD8 expression: report of 10 cases and immunochemical analysis of the CD8 antigen. Br J Haematol 1998;103:157-162. (Pubitemid 28470813)
74. Parisi-Duchene E, Mazurier I, Moskovtchenko P. Aberrant CD8 expression in B-chronic lymphocytic leukemia: report of five cases. Acta Haematol 2006;115:74-77. (Pubitemid 43130437)
75. Schroers R, Pukrop T, Durig J, et al. B-cell chronic lympho cytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. Leuk Lymphoma 2004;45:1677-1681. (Pubitemid 38886015)
76. Stagno F, Triolo A, Del Fabro V, et al. Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells. Lab Hematol 2009;15:1-3.
77. Attadia V, Alosi M, Improta S, et al. Immunophenotypic and molecular genetic characterization of a case of CD8 + B cell chronic lymphocytic leukemia. Leukemia 1996;10:1544-1550. (Pubitemid 26290341)
78. Brunet C, Bardin N, Oukhouya O, et al. A case report: CD8 expression in B-cell chronic lymphocytic leukemia (B-CLL). Prognostic signifi cance of the aberrant CD8 expression. Hematol Cell Ther 1998;40:279-282. (Pubitemid 29016377)
79. Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, et al. Prognostic signifi cance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1829-1836.
80. Paul P, Cabestre FA, Ibrahim EC, et al. Identifi cation of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000;61:1138-1149. (Pubitemid 32043892)
81. Nuckel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodefi ciency in chronic lymphocytic leukemia. Blood 2005;105:1694-1698. (Pubitemid 40223692)
82. Erikci AA, Karagoz B, Ozyurt M, et al. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 2009;14:101-105.
83. Kinoshita K, Honjo T. Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol 2001;2:493-503. (Pubitemid 33673399)
84. Heintel D, Kroemer E, Kienle D, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004;18:756-762. (Pubitemid 38500194)
85. McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 2003;101:4903-4908. (Pubitemid 36857752)
86. Palacios F, Moreno P, Morande P, et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 2010;115:4488-4496.
87. Meyaard L, Adema GJ, Chang C, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997;7:283-290. (Pubitemid 27392019)
88. Poggi A, Catellani S, Bruzzone A, et al. Lack of the leukocyteassociated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008;22:980-988. (Pubitemid 351689880)
89. Alatrash G, Albitar M, O ' Brien S, et al. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fl udarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148:386-393.
90. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010;23:133-143.
91. Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002;23:285-290. (Pubitemid 34628770)
92. Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+ CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:1180-1183. (Pubitemid 40664020)
93. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-568.
94. Pallasch CP, Ulbrich S, Brinker R, et al. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009;33:460-464.
95. Wong KK, Khatri I, Shaha S, et al. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010;88:361-372.
96. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol Rev 2003;195:58-71. (Pubitemid 37153453)
97. Zlotnik A, Yoshie O. Chemokines: a new classifi cation system and their role in immunity. Immunity 2000;12:121-127. (Pubitemid 30398626)
98. Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-3325. (Pubitemid 350106325)
99. Kipps T. Chronic lymphocytic leukemia and related disorders. In: Beutler E, Lichtman MA, Coller BS, et al., editors. William ' s hematology. New York: McGraw-Hill; 1995. p 1017.
100. Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell diff erentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000;95:1199-1206. (Pubitemid 30099827)
101. Kim KM, Reth M. Signaling diff erence between class IgM and IgD antigen receptors. Ann NY Acad Sci 1995;766:81-88. (Pubitemid 26169084)
102. Cutrona G, Colombo M, Matis S, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica 2008;93:413-422. (Pubitemid 351398643)
103. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing diff erent antibody reactivity. J Clin Invest 2005;115:1636-1643. (Pubitemid 40814672)
104. Ligler FS, Kettman JR, Smith RG, et al. Immunoglobulin phenotype on B cells correlates with clinical stage of chronic lymphocytic leukemia. Blood 1983;62:256-263. (Pubitemid 13036070)
105. Shen PU, Fuller SG, Rezuke WN, et al. Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001;116:905-912. (Pubitemid 33108163)
106. Bojarska-Junak A, Hus I, Sieklucka M, et al. Natural killer-like T CD3+ /CD16+ CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol Rep 2010;24:803-810.
107. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-4093. (Pubitemid 35332051)
108. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
109. Quijano S, Lopez A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008;74:139-149. (Pubitemid 351656293)
110. Hulkkonen J, Vilpo L, Hurme M, et al. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and Effects of chromosomal abnormalities. Leukemia 2002;16:178-185. (Pubitemid 34145134)
111. Zucchetto A, Bomben R, Dal Bo M, et al. A scoring system based on the expression of six surface molecules allows the identifi cation of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol 2006;207:354-363.
112. Zucchetto A, Sonego P, Degan M, et al. Surface-antigen expression profi ling of B cell chronic lymphocytic leukemia: from the signature of specifi c disease subsets to the identifi cation of markers with prognostic relevance. J Transl Med 2006;4:11.
113. Zucchetto A, Sonego P, Degan M, et al. Surface-antigen expression profi ling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): identifi cation of markers with prognostic relevance. J Immunol Methods 2005;305:20-32. (Pubitemid 41416718)
114. Hjalmar V, Kimby E, Matutes E, et al. Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. Haematologica 1998;83:602-609. (Pubitemid 28364071)
115. Juliusson G, Oscier D, Gahrton G; for the International Working Party on Chromosomes in CLL (IWCCLL). Cytogenetic fi ndings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 622 patients. Leuk Lymphoma 1991;5:21-25.
116. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
117. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71-84.
118. Eisele L, Prinz R, Klein-Hitpass L, et al. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 2009;83:320-327.
119. Friedrichs B, Siegel S, Reimer R, et al. High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. Leuk Res 2011;35:721-729.
120. Mansouri M, Sevov M, Fahlgren E, et al. Lipoprotein lipase is diff erentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res 2010;34:301-306.
121. Kotaskova J, Tichy B, Trbusek M, et al. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn 2010;12:328-334.
122. Li S, Moff ett HF, Lu J, et al. MicroRNA expression profi ling identifi es activated B cell status in chronic lymphocytic leukemia cells. PLoS One 2011;6:e16956.
123. Penna G, Allegra A, Alonci A, et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 2010 May 22. [Epub ahead of print]
124. Zhu HJ, Xu W, Cao X, et al. Detection of PUMA mRNA levels by real-time quantitative RT-PCR in chronic lymphocytic leukemia and its clinical signifi cance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18: 843-848.
125. Josefsson P, Geisler CH, Leff ers H, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007;109:4973-4979. (Pubitemid 46827796)
126. Hassanein NM, Perkinson KR, Alcancia F, et al. A single tube, four-color fl ow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. Am J Clin Pathol 2010;133:708-717.
127. Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549-557. (Pubitemid 43899758)
128. Th ornton PD, Fernandez C, Giustolisi GM, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004;5:145-151. (Pubitemid 38519264)
129. Hsi ED, Kopecky KJ, Appelbaum FR, et al. Prognostic signifi cance of CD38 and CD20 expression as assessed by quantitative fl ow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2003;120:1017-1025. (Pubitemid 36411561)
130. Del Principe MI, Del Poeta G, Venditti A, et al. Clinical signifi cance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica 2004;89:1468-1475. (Pubitemid 39643514)
131. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical signifi cance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17:683-690.
132. D'A rena G, Tarnani M, Rumi C, et al. Prognostic signifi cance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 2007;82:787-791. (Pubitemid 350194506)
133. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-2451. (Pubitemid 350148886)
134. Weinberg JB, Volkheimer AD, Chen Y, et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007;82:1063-1070. (Pubitemid 350209847)
135. HusI, Bojarska-Junak A, Dmoszynska A, et al. ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. Folia Histochem Cytobiol 2008; 46:147-152.
136. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112:1923-1930.
137. Xu W, Li JY, Wu YJ, et al. CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009;33:237-243.
138. Morabito F, Cutrona G, Gentile M, et al. Defi nition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009;146:44-53.
139. Hock BD, McKenzie JL, McArthur L, et al. CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data. Intern Med J 2010;40:842-849.